30 March 2022 - 12 agenda items for consideration at the 28-29 July 2022 meeting.

The assessments of note are:

• A prognostic RT-qPCR test for prediction of risk of distant recurrence of breast cancer under endocrine treatment (third application)
• Testing of tumour tissue to determine a positive homologous recombination deficiency status in women newly diagnosed with advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian tube or primary peritoneal cancer for access to PBS olaparib
• Whole body magnetic resonance imaging for detection of cancer in individuals with germline pathogenic TP53 variants
• Lutetium Lu 177 vipivotide tetraxetan for metastatic castrate resistant prostate cancer
• Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell to treat refractory or relapsed multiple myeloma

Read MSAC agenda